Skip to main content
ScholarsBetaWeill Cornell Medicine

Overview

Dr. Robinson is a board-certified Anatomic Pathologist with subspecialty expertise and interest in Genitourinary Pathology. After finishing his residency training at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, he completed a clinical and research fellowship in Urologic Pathology at The Johns Hopkins Hospital in Baltimore, Maryland. His research focuses on the pathogenesis, diagnosis, and treatment of bladder, kidney, and prostate cancers.

Dr. Robinson has co-authored more than 120 peer-reviewed publications, edited two textbooks, and written multiple textbook chapters on both benign and malignant urologic diseases.  He is Director of the Experimental Pathology Shared Resource for Weill Cornell's Meyer Cancer Center, and he co-leads the Biospecimen Core for Cornell's SPORE in prostate cancer.  He sits on several expert panels for prostate, bladder, and upper urinary tract malignancies, and he serves on the Editorial Board for the Archives of Pathology & Laboratory Medicine and BMC Cancer.  

In addition to his research activities, he serves as Vice Chair for Anatomic Pathology and is active in medical student, resident, and fellow education.

Highlights

  1. 1
    Urologic oncology · 2022
    CGChristopher GaffneyJEJonathan E. ShoagJJJiangling Jenny TuFKFrancesca Khani+4 more →BDBrian D. Robinson
    PMID: 35490048PMCID: PMC9117451DOISenior author5 citations

Publications

219 publications

Funding

20 grants

Active

9 grants
  • Co-I
    The role of early oncogenic drivers in maintaining lineage fidelity in prostate cancer
    National Cancer Institute · 2025–2030
    R01CA301637-01
  • Co-I
    Upstream and downstream targeting of the SPOP ubiquitin signaling pathway in prostate cancer
    National Cancer Institute · 2024–2029
    R01CA287724-01A1
  • Co-I
    Pelvic fascia spARing radical prostatectomy TrIAL (PARTIAL)
    National Cancer Institute · 2022–2028
    R01CA259173-02
  • Co-I
    "DNMT and TET1 reprogramming as a targetable mechanism of resistance in advanced prostate cancer"
    National Cancer Institute · 2023–2028
    R01CA274963-01A1
  • Co-I
    Predicting off-target resistance to androgen receptor signaling inhibitors from histology slides using foundation models
    Prostate Cancer Foundation · 2026–2028
    PCF 252114-01
  • Co-I
    Investigating cell-intrinsic and extrinsic interactions in prostate cancer at the single cell level ("Core A: Pathobiology")
    National Cancer Institute · 2022–2027 · via Columbia University
    P01CA265768-01
  • Co-I
    Genomic Diversity of Prostate Cancer Across the African Diaspora
    National Cancer Institute · 2022–2027 · via Dana-Farber Cancer Institute
    R01CA259200-01A1
  • Co-I
    Novel Complex Structural Variants And Epigenetic Alterations Link The Genomes Of Prostate Cancer In African Americans With Outcome Disparity.
    U.S. Department of Defense · 2021–2026
    W81XWH-21-1-0762
  • Co-I
    PSMA/MR-guided Stereotactic Body Radiotherapy for High Risk Prostate Cancer
    National Cancer Institute · 2020–2025
    R01CA249615-02
Completed grants (11)
  • Co-I
    Collaborative genomic alterations and transcriptional control in prostate cancer
    National Cancer Institute · 2019–2025
    R01CA233650-05
  • Co-I
    Coordinate Regulation of Oncogenic Signaling Pathways in SPOP Mutant Prostate Cancer
    National Cancer Institute · 2018–2025
    R37CA215040-06
  • PI
    Characterizing the genomic landscape of adult onset Wilms' tumors to generate faithful preclinical models for therapeutic testing
    Starr Cancer Consortium · 2021–2024
    I14-0024
  • Co-I
    Unraveling the landscape of homologous recombination deficiency in patients with breast and prostate cancer across the African diaspora in NYC
    New York Genome Center Inc. · 2020–2024
    NYG 204878-01
  • Co-I
    Defining Molecular Determinants of Lineage Plasticity as a Mechanism of Treatment Resistance in Prostate Cancer
    National Cancer Institute · 2019–2024
    R01CA230913-01A1
  • Co-I
    Temporal Evolution of N-Myc Signalign and Early Targeting of the Neuroendocrine Phenotype in Prostate Cancer
    U.S. Department of Defense · 2017–2023
    W81XWH-17-1-0652
  • Co-I
    Weill Cornell Medicine (WCM) SPORE in Prostate Cancer
    National Cancer Institute · 2017–2023
    P50CA211024-05
  • Co-I
    Defining the Potential of Early Molecular Subtypes of Prostate Cancer to Progress to AR-Indifferent Disease
    U.S. Department of Defense · 2019–2022
    W81XWH-19-1-0403
  • Co-I
    Subtype-specific modes of clinical and molecular progression in prostate cancer
    Damon Runyon Cancer Research Foundation · 2019–2022
    88C-16
  • Co-I
    Precision Interception of Aggressive Prostate Cancer in African American Men
    National Cancer Institute · 2019–2021 · via Dana-Farber Cancer Institute
    P20CA233255-01
  • KP
    The Prostate Cancer Tumor Microenvironment Exhibits Differentially Expressed Gene
    National Cancer Institute · 2014–2015 · via University of California, Irvine
    U01CA152738-05

Clinical research

1 study

Active

1 study
  • PI
    Weill Cornell Medicine Institutional Biorepository & Database
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)

News mentions

1 mentionView all WCM news ↗

External relationships

Professional Services

Universita Vita-Salute San Raffaele